The FDA today approved defibrotide sodium (Defitelio, Jazz Pharmaceuticals) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they undergo a hematopoietic stem cell transplant (HSCT). This is the first FDA-approved therapy for treatment of severe hepatic VOD, a rare and life-threatening liver condition.